Related Experiment Videos
Review of efficacy parameters
1Hôpital Laënnec, Paris, France.
Insights
Aprotinin use in pediatric cardiac surgery may reduce bleeding and inflammation, but more research is needed. Further trials are required to assess its effects on platelet preservation and determine optimal dosages for neonates.
Area of Science:
- Cardiovascular Surgery
- Pediatric Medicine
- Pharmacology
Background:
- Pediatric cardiopulmonary bypass (CPB) carries greater risks than in adults.
- Aprotinin is explored to mitigate CPB-induced complications by influencing hemostasis.
Purpose of the Study:
- To review existing literature on aprotinin's efficacy and safety in pediatric cardiac surgery.
- To identify gaps in current research regarding aprotinin use in this population.
Main Methods:
- Systematic literature review of studies on aprotinin in pediatric cardiac surgery.
- Analysis of study design, patient populations, and reported outcomes.
Main Results:
- Existing studies often lack placebo controls, have heterogeneous populations/procedures, and omit aprotinin plasma concentration data.
- Variations in dosing, heparin-protamine protocols, and CPB priming complicate result comparisons.
Conclusions:
- Further trials are essential to evaluate aprotinin's impact on platelet preservation, especially in neonates.
- Aprotinin may reduce fibrinolytic and platelet activation, offering clinical benefits in specific pediatric cardiac surgery patient groups.
- Optimal aprotinin dosages for specific objectives require further determination.
Background:
The deleterious effects of cardiopulmonary bypass are greater in pediatric patients than in adults. The use of aprotinin to manipulate hemostasis has become an important factor in attempts to reduce adverse consequences of these effects.
Methods:
This article reviews the literature on the use of aprotinin in pediatric cardiac surgery.
Results:
Available studies have many deficiencies, often including lack of placebo control, nonhomogeneous populations and procedures, and absence of information on aprotinin plasma concentrations. Comparison of trial results is further complicated by differences in dose regimens, heparin-protamine protocols, and priming.
Conclusions:
Further trials are required to adequately assess aprotinin effect on platelet preservation, particularly in neonates, to evaluate aprotinin's antiinflammatory action, and to determine optimum dosages to achieve specific objectives. Aprotinin in pediatric cardiac surgery has been found to be associated with no adverse effects, to decrease fibrinolytic and probably platelet activation, and to offer important clinical benefits in specific groups of patients.